Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma | JNJ Stock News

Johnson & Johnson's CARVYKTI® demonstrated long-term efficacy in relapsed/refractory multiple myeloma, with 33% of patients achieving over five years of progression-free survival after a single infusion, as shown in the CARTITUDE-1 study. The median overall survival for these patients reached 60.7 months, with a subset maintaining minimal residual disease negativity throughout the follow-up. While the safety profile remained consistent with prior data, two new cases of second primary malignancies were reported, and CARTITUDE-4 data showed enhanced survival benefits across patient subgroups, suggesting CARVYKTI® could redefine treatment strategies by offering long-lasting remission.

Analysis

Johnson & Johnson's CARVYKTI® has demonstrated significant long-term efficacy in treating relapsed/refractory multiple myeloma, with pivotal data from the CARTITUDE-1 study showing that 33% of patients (32 out of 97) achieved progression-free survival for over five years after a single infusion, without requiring maintenance or subsequent anti-myeloma therapy. This is a substantial development for a heavily pre-treated patient population, who had undergone a median of six prior lines of therapy, and for whom a median overall survival of 60.7 months was observed. Furthermore, all 12 patients in a monitored subset maintained minimal residual disease negativity throughout the five-year follow-up, underscoring the depth and durability of response. While the safety profile remained consistent with prior reports, with no new Parkinsonism events or cranial nerve palsies, two new cases of solid tumors as second primary malignancies were reported, a factor requiring ongoing surveillance. Complementary data from the CARTITUDE-4 study further supports CARVYKTI®'s potential, showing enhanced progression-free and overall survival benefits across diverse patient subgroups, including those with standard and high-risk cytogenetics and extramedullary disease, suggesting a broad applicability and the potential to redefine treatment paradigms by offering long-lasting remission from a single treatment.

Key Decisions for Investors

• The compelling long-term efficacy data for CARVYKTI®, demonstrating over five years of progression-free survival in a third of heavily pre-treated patients with a single infusion, significantly bolsters Johnson & Johnson's oncology portfolio and supports a positive outlook for the drug's revenue contribution.
• Investors should carefully monitor the emerging data and regulatory discourse surrounding second primary malignancies, as this represents a key risk factor that, while currently limited, could influence CARVYKTI®'s risk-benefit perception and market adoption despite its strong efficacy.
• Consider the potential for market expansion of CARVYKTI® into earlier lines of therapy, as suggested by the CARTITUDE-4 subgroup analyses, which could substantially increase its commercial opportunity and impact on JNJ's growth within the competitive multiple myeloma landscape.